# A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

> **NCT03549000** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 127 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)
- Triple Negative Breast Cancer (TNBC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Colorectal Cancer Microsatellite Stable (MSS)
- Ovarian Cancer
- Renal Cell Carcinoma (RCC)
- Metastatic Castration Resistant Prostate Cancer (mCRPC)

## Interventions

- **OTHER:** NZV930
- **OTHER:** PDR001
- **DRUG:** NIR178

## Key facts

- **NCT ID:** NCT03549000
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-18
- **Primary completion:** 2022-10-17
- **Final completion:** 2022-10-17
- **Target enrollment:** 127 (ACTUAL)
- **Why stopped:** After review of data which showed low likelihood of efficacy in these patients Novartis decided to terminate the trial early. Termination was not safety related
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03549000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03549000, "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03549000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*